Tier 2, Investigational, human data
Studied in registered human trials with published pharmacokinetic data, but not approved. Dosing outside a trial protocol has no established safety margin.
Half-life
11.5 days · human data · subcutaneous
Phase 1b multiple-ascending-dose study reported T1/2 ranging 150.9-403.5 h (6.3-16.8 days) across doses; median Tmax 72 h. Wide inter-dose range. MW 4476 from PubChem name lookup.
Dosing
1000 - 9000 mcg
Phase 1b used weekly up-titration cohorts within 1.0-6.0 mg; phase 2 tested up to 9 mg once weekly. Investigational.
Titration
Investigational; weekly up-titration (e.g., 1.0→3.0 mg, 1.5→4.5 mg, 2.0→6.0 mg cohorts in phase 1b).
Frequency
Once weekly (investigational)
Regulatory status
Investigational (Innovent / Eli Lilly), oxyntomodulin-analog GLP-1R/GCGR dual agonist. Under regulatory review in China; not FDA-approved.
Evidence base
human clinical · confidence: high
Published phase 1b/phase 2 trials with reported pharmacokinetics; no FDA label.
Safety
Investigational; no boxed warning. Trial adverse events predominantly gastrointestinal (nausea, diarrhea, decreased appetite). Not for clinical dosing decisions.